` AUROPHARMA (Aurobindo Pharma Ltd) vs BSE Sensex 30 Comparison - Alpha Spread

AUROPHARMA
vs
BSE Sensex 30

Over the past 12 months, AUROPHARMA has underperformed BSE Sensex 30, delivering a return of 6% compared to the BSE Sensex 30's 6% growth.

Stocks Performance
AUROPHARMA vs BSE Sensex 30

Loading

Performance Gap
AUROPHARMA vs BSE Sensex 30

Loading
AUROPHARMA
BSE Sensex 30
Difference

Performance By Year
AUROPHARMA vs BSE Sensex 30

Loading
AUROPHARMA
BSE Sensex 30
Add Stock

Competitors Performance
Aurobindo Pharma Ltd vs Peers

BSE Sensex 30
AUROPHARMA
LLY
JNJ
NOVO B
ROG
Add Stock

Aurobindo Pharma Ltd
Glance View

Economic Moat
None
Market Cap
708.6B INR
Industry
Pharmaceuticals

Aurobindo Pharma Ltd., founded in 1986 by P.V. Ramprasad Reddy and K. Nityananda Reddy, began its journey in the bustling pharmaceutical landscape of Hyderabad, India. Initially starting as a provider of semi-synthetic penicillin, the company gradually diversified its product portfolio across major therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, and anti-diabetics, among others. With an entrepreneurial vision, Aurobindo leveraged vertical integration to optimize costs and operations—manufacturing everything from raw active pharmaceutical ingredients (APIs) to finished dosage formulations. This strategic approach not only reinforced its cost-leadership position but also enabled the company to meet stringent regulatory requirements in global markets, providing them a competitive edge. In its quest for expansion, Aurobindo penetrated international markets, including the United States and Europe, through acquisitions and strategic alliances, expanding its manufacturing capabilities and distribution networks. The company generates its revenue primarily through the sale of generic pharmaceuticals, which are manufactured in their state-of-the-art facilities and sold worldwide. Aurobindo's robust research and development (R&D) investments have further fueled its growth by enabling the company to introduce new and complex product lines, including biosimilars and specialty generics. This blend of strategic foresight, operational excellence, and commitment to innovation is what propels Aurobindo Pharma's ongoing narrative in the global pharmaceutical industry.

AUROPHARMA Intrinsic Value
1 120.33 INR
Overvaluation 8%
Intrinsic Value
Price
Back to Top